Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Monoclonal Antibody HuHMFG1 in Treating Women With Locally Advanced or Metastatic Breast Cancer

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: November 9, 2004
Last updated: June 25, 2013
Last verified: April 2007

RATIONALE: Monoclonal antibodies such as HuHMFG1 can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.

PURPOSE: This phase I trial is studying the side effects and best dose of monoclonal antibody HuHMFG1 in treating women with locally advanced or metastatic breast cancer.

Condition Intervention Phase
Breast Cancer
Biological: monoclonal antibody HuHMFG1
Phase 1

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label Phase I Study of Humanized Human Milk Fat Globule-1 (huHMFG1) Antibody in Patients With Locally Advanced or Metastatic Breast Cancer (TOPCAT)

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Estimated Enrollment: 24
Study Start Date: May 2004
Study Completion Date: December 2007
Detailed Description:


  • Determine the safety and tolerability of monoclonal antibody HuHMFG1 in women with locally advanced or metastatic breast cancer.
  • Determine a safe recommended dose and schedule of this drug in these patients.
  • Determine the pharmacokinetic profile, in the absence of any other chemotherapy or endocrine agent, of this drug in these patients.
  • Determine the antitumor activity of this drug in these patients.
  • Determine time to progression in patients treated with this drug.
  • Assess immunological markers (e.g., granzyme B, gamma interferon, and C1Q) for determining response to this drug in these patients.
  • Assess markers of immunogenicity (e.g., human anti-human antibody) of this drug in these patients.
  • Assess tumor markers (e.g., CA15.3 and CEA) in patients treated with this drug.
  • Correlate, preliminarily, soluble HMFG1 antigen levels with pharmacokinetic data for this drug in these patients.

OUTLINE: This is an open-label, non-randomized, dose-escalation study.

Patients in cohorts 1 and 2 receive monoclonal antibody HuHMFG1 IV over 1-3 hours once every 21 days for doses 1 and 2. All subsequent dose intervals are based on individual half-life value of the drug, to be within 3 days of the estimated half-life in multiples of 7 days. Patients in cohorts 3 and 4 receive monoclonal antibody HuHMFG1 at the dosing interval determined in the first 2 cohorts. Treatment continues in the absence of disease progression or unacceptable toxicity.

Cohorts of 6 patients receive escalating doses of monoclonal antibody HuHMFG1 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity.

All patients are followed at 4 weeks and then every 6 weeks for 6 months. Patients with an antitumor response or stable disease are followed every 12 weeks until disease progression or initiation of another antitumor treatment.

PROJECTED ACCRUAL: A total of 6-24 patients will be accrued for this study within 18 months.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed breast cancer

    • Locally advanced or metastatic disease
    • No inflammatory breast cancer
  • Measurable (RECIST) or evaluable disease (e.g., cytologically or radiologically detectable disease that does not fulfill RECIST criteria)
  • Failed prior OR not a candidate for OR refused anthracycline- and taxane-containing chemotherapy
  • Patients whose tumor overexpresses HER-2 must have failed prior trastuzumab (Herceptin®)
  • No known CNS metastases
  • No metastases accessible to complete surgical resection
  • Unstained slides cut from formalin-fixed and paraffin-embedded tumor blocks available

    • Appropriate tumor block also acceptable
  • Hormone receptor status:

    • Not specified



  • 18 and over


  • Female

Menopausal status

  • Not specified

Performance status

  • WHO 0-1

Life expectancy

  • At least 4 months


  • Hemoglobin ≥ 10 g/dL
  • Absolute neutrophil count ≥ 1,500/mm^3
  • WBC ≥ 1,000/mm^3
  • Platelet count ≥ 100,000/mm^3


  • Bilirubin ≤ 1.5 mg/dL
  • ALT or AST ≤ 2.5 times upper limit of normal (ULN) (< 5 times ULN in patients with liver metastases) OR
  • Alkaline phosphatase ≤ 2.5 times ULN (< 5 times ULN in patients with liver metastases)

    • Any degree of elevated alkaline phosphatase allowed provided it is due to bone metastases


  • Creatinine ≤ 1.5 times ULN OR
  • Creatinine clearance > 60 mL/min
  • Uric acid < 1.25 times ULN (for patients with hyperuricemia only)
  • Calcium (corrected for serum albumin) < 11.5 mg/dL (for patients with hypercalcemia only)


  • LVEF ≥ 45% by MUGA or echocardiogram within the past 4 weeks


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective barrier contraception
  • No other malignancy within the past 5 years except adequately treated nonmelanoma skin cancer or cervical intra-epithelial neoplasia
  • No other uncontrolled illness that would preclude study participation


Biologic therapy

  • See Disease Characteristics
  • Prior biological therapy allowed
  • More than 2 weeks since prior blood transfusions or growth factors to aid hematological recovery
  • No other concurrent antitumor immunotherapy


  • See Disease Characteristics
  • More than 4 weeks since prior cytotoxic chemotherapy
  • No more than 3 prior chemotherapy regimens, including adjuvant/neoadjuvant therapy
  • No concurrent antitumor chemotherapy

Endocrine therapy

  • Prior hormonal therapy allowed
  • No concurrent corticosteroids except as physiologic replacement and/or for acute short-term treatment of, or prophylaxis against, infusion reactions
  • No concurrent antitumor hormonal therapy


  • See Disease Characteristics
  • More than 4 weeks since prior radiotherapy (except for palliative radiotherapy)
  • No concurrent antitumor radiotherapy, except for palliation to non-study lesions

    • Irradiated area should be as small as possible and involve ≤ 10% of the bone marrow in any given 4-week period


  • More than 4 weeks since prior major surgery


  • More than 30 days since prior investigational agents
  • No other concurrent investigational agents
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00096057

United States, California
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California, United States, 90095-1781
United States, Colorado
University of Colorado Cancer Center at UC Health Sciences Center
Aurora, Colorado, United States, 80045
United States, Texas
M.D. Anderson Cancer Center at University of Texas
Houston, Texas, United States, 77030-4009
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Study Chair: Mark D. Pegram, MD Jonsson Comprehensive Cancer Center
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00096057     History of Changes
Other Study ID Numbers: ROCHE-NP17787
CDR0000391212 ( Registry Identifier: PDQ (Physician Data Query) )
Study First Received: November 9, 2004
Last Updated: June 25, 2013

Keywords provided by National Cancer Institute (NCI):
recurrent breast cancer
stage IIIA breast cancer
stage IIIB breast cancer
stage IIIC breast cancer
stage IV breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs processed this record on April 26, 2017